Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Shareholder Update Q3 2018 Highlights: Venous leg ulcer Phase 2 trial on track: top-line results mid-NovemberDiabetic foot ulcer pilot clinical study: in development with key US researchersOcular wounds: international patent applications filedOcular orphan drug designation application: 2018 submission on track ----------------------------------------------------- BRISBANE, Australia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Dear Shareholders As the key milestone of completing our Phase 2 clinical trial (VF00102) of VF001 for venous leg ulcers (VLU) approaches, I would like to take this op...
Phase 2 Clinical Trial for Venous Leg Ulcers Nears Completion BRISBANE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce that the Company’s Phase 2 clinical trial VF00102, for the treatment of venous leg ulcers (VLU), is approaching the end of its treatment phase. “Since finalising recruitment in July, the study has progressed to schedule and there are now only eight patients left to complete treatment. We expect the last patient to ...
Factor Therapeutics expects to report top-line results before the end of the year from its randomised Phase IIb trial of VF-001 in venous leg ulcer (VLU) patients. The trial has been designed to recruit patients with VLU with moderate severity, the subgroup that responded best to VF-001 in a previous Phase II trial. Positive results would enable submission for CE mark approval in Europe and clear the way to pivotal Phase III studies in the US. We roll our risked NPV model forward following relea...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Factor Therapeutics is developing VF-001, an advanced wound care product that promotes healing in chronic wounds. It is about to commence a randomised Phase IIb trial targeting venous leg ulcers, with top-line results anticipated in Q417. There is an urgent need for better therapies for this condition, with 40-70% of ulcers remaining unhealed after six months of the best current treatments. We value Factor at A$102m or A$0.14/share.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.